The potential use of soluble sLOX-1 as a biomarker for acute myocardial infarction and stroke presents a promising opportunity to enhance the current diagnostic landscape, which relies on established cardiac biomarkers such as cardiac troponins and creatine kinase-MB (CK-MB). The gene discussed is OLR1; the disease is myocardial infarction.